Dave Williamson
XMFGreenwave4
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Recent Articles by Dave Williamson

Apr 7, 2017
by Dave Williamson
Is Bristol a Buy Post-Plavix

Apr 7, 2017
by Dave Williamson
Why This Biotech Crushed the Market

Apr 7, 2017
by Dave Williamson
Is This Biotech Upgrade Deserved?

Apr 7, 2017
by Dave Williamson
Avoid These 2 Plunging Biotechs

Apr 7, 2017
by Dave Williamson
This Biotech Is No One-Trick Pony

Apr 7, 2017
by Dave Williamson
3 Health-Care Stocks' Monster Moves

Apr 7, 2017
by Dave Williamson
Why These 2 Biotechs Are Soaring
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.